Delcath (NSDQ:DCTH) said today it priced a follow-on offering of 9.3 million units of stock it plans to float at 75¢ per share, slated to bring in $7 million for the company. Each unit in the offering consists of a share of common stock, 0.75 of a Series A warrant to purchase common stock at 87¢, a […]
Delcath Systems Inc.
Delcath to settle shareholder suits for $8.5m
Delcath (NSDQ:DCTH) said yesterday that it agreed to pay $8.5 million to settle a clutch of lawsuits filed by shareholders over losses related to its development of the drug-device combination Melblez kit. The lawsuits, filed by shareholders in 2013, sought compensation for losses between April 21, 2010, and May 2, 2013, stemming from 3 separate incidents the plaintiffs claim caused […]
Delcath expands Phase II trial
Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.
Stryker hits a new lifetime high in shares | Medtech Wall Street news for the week of Apr. 7, 2014
Delcath Systems tanks following reverse stock split
Medtech personnel moves for the week of Mar. 10, 2014
ConMed proxy war gets ugly
February 28, 2014 by Brad Perriello
The proxy war over control of the board at ConMed turned ugly this week after serious allegations surfaced against 1 of the medical device company’s nominees for director.
Medtronic vet takes over marketing at Vexim | Personnel Moves
Neuro Kinetics appoints new CFO | Personnel Moves
Neuro Kinetics appointed Michael Saporito as its new CFO.
Saporito joins the Pittsburgh-based medical device company after years with LifeVest, which he helped turn around before the company was bought out by Zoll Medical.
Troubled Delcath announces $7.5M offering, drops 23%
New York’s Delcath Systems (NSDQ:DCTH) is looking to raise about $7.5 million through sales of common stock, planning on using the funds for working capital, commercialization efforts, clinical trials and other "general corporate purposes."